Sidley’s Eva von Mühlenen in Geneva and Josefine Sommer in Brussels talk to oncologist Wolfgang Hackl — the founder of a FemTech startup that guides doctors in the treatment of breast cancer — about regulation, research and development (R&D), and the vast potential of artificial intelligence in the field of health technology for women.
In this video recording, our lawyers talk to their guest about the challenges that his company, OncoGenomX, has faced, on both the R&D and marketing authorization sides, in developing a tool to help doctors decide on courses of treatment for women. They discuss the conditions needed to grow the field of FemTech applications of artificial intelligence in an environment where only 1% of R&D efforts are currently invested in conditions specific to women. They also talk about why it is crucial for innovative companies in this space to engage early and openly with regulators.
Read more on our previous blog post: Why Venture Capital Investors Are Focused on FemTech.
This is the second in a series of video interviews, ‘FemTech in the Spotlight’. The first part can be viewed here: FemTech in the Spotlight – An Interview with REA Co-Founders
This post is as of the posting date stated above. Sidley Austin LLP assumes no duty to update this post or post about any subsequent developments having a bearing on this post.